Cybin (CYBN.NE) in Prime Position as Interest in Psychedelic Medicine Surges

03/25/2021

Cybin (CYBN.NE) is in a prime position as the push for psychedelic medicine surges across North America and around the world. Scientific evidence supports the life-changing impact of medicinal mushrooms as a safe and natural alternative for treating mental illness of all types. Cybin stands at the forefront of the medicinal psychedelics sector boasting ten provisional patents and strong clinical pipeline with phase 2 trials underway. However, Cybin is not alone in their pursuit of normalized psychedelic medicine. Companies like Mind Medicine, Numinus Wellness, and Red Light Holland are all committed to providing better treatments for the millions suffering from mental health issues.

Mental illness tends to get swept under the rug in a lot of instances and, as a result, many are left without a proper diagnosis or access to the treatment they need. Furthermore, barriers like social stigma, denial, and fear of treatment prevent a shocking majority from ever seeking help. More than 700 million people worldwide struggle with some form of mental illness such as depression, addiction, or post-traumatic stress disorder (PTSD). More specifically, one in four people face a mental or neurological disorder at some point in their lives.¬†Keep in mind, the 700 million total only accounts for those who did seek help, not those who didn’t.

With this in mind, the current treatments available are often inadequate and provide limited efficacy. It has become apparent that dominant models of mental health care struggle to meet the complex challenges of mental illness. As a result, an increasing number of people are turning to alternative treatments like psychedelic medicine. In particular, psilocybin mushrooms have been the talk of the town lately, proving their effectiveness as a treatment for various mental illnesses. For example, research from a number of organizations including Johns Hopkins, revealed that patients with depressive orders had a clinically significant positive response to psilocybin-assisted therapy.

You’re here for the meat of this article though, aren’t you? What does this mean for you, the investor? As scientific research continues to generate validity, support for psilocybin as an alternative treatment has increased. As a result, the psychedelic therapeutics sector has seen some major upticks in both new companies entering the space as well as with investors who are optimistic of the possibilities. Stakeholders in this emerging market are scouting for companies that can shoulder the pricey process of clinical trials and can bring a drug to the market. Cybin certainly fits this bill and shows incredible potential in the industry as it continues to evolve.

The Company stands at the forefront of the mental health therapeutics revolution and is developing a new class of psychedelic medicines and treatment protocols. Moreover, Cybin is built upon a solid foundation of employees. Cybin’s CEO Doug Drysdale has three decades of experience in the health-care sector. Additionally, the Company has no issue rallying support and fundraising, having raised C$45 million in the Canadian psychedelic sector and C$88 million across Seed, Series-A and Series-B financial rounds.

Cybin has its roots deeply ingrained in the psychedelic sector with various clinical studies, acquisitions, and a diverse portfolio under its belt. The Company has performed exceptionally in the new year and will continue to find success as psilocybin as an alternative medicine becomes increasingly normalized.

Cybin’s stock price opened at $1.42 today and quickly spiked to $1.45. The stocks price currently sits at $1.44.

Disclaimer: Cybin is a client of Equity Guru.

 

Related Posts

Latest Post

Leave a Reply

Your email address will not be published. Required fields are marked *